Oncolytic virus therapy
A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.
1. A method of treating a human subject with cancer, comprising
administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein
the virus binds specifically to the leukocytes; and
the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:100,
thereby treating the subject:
wherein the leukocytes comprise an immortalized cell line.
2. The method of claim 1 , wherein the immortalized cell line is U-937 or KG-1.
3. A method of treating a human subject with cancer, comprising
administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein
the virus binds specifically to the leukocytes, and
the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:100,
thereby treating the subject;
wherein the pharmaceutical composition comprises the oncolytic virus suspended in whole blood.
4. A method of treating a human subject with cancer, comprising
administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein
the virus binds specifically to the leukocytes; and
the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:100,
thereby treating the subject;
wherein the composition is administered intravesicularly.
5. The method of claim 4 , wherein the volume of composition administered is up to seventy-five milliliters.
6. The method of claim 5 , wherein the volume of composition administered is from fifty to sixty milliliters.
7. A method of treating a human subject with cancer, comprising
administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution,
wherein the cells are leukocytes or platelets, thereby treating the subject;
wherein the cells comprise an immortalized cell line.
8. The method of claim 7 , wherein the immortalized cell line is U-937 or KG-1.
9. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are platelets, thereby treating the subject.
10. A method or treating a human subject with cancer, comprising
administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution,
wherein the cells are leukocytes or platelets, thereby treating the subject;
wherein the infected cells are at least one-tenth of one percent of the total number of leukocytes and platelets in the composition.
11. The method of claim 10 , wherein the infected cells are at least thirty percent of the total number of leukocytes and platelets in the composition.
12. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are platelets, thereby treating the subject; wherein the effective amount is a daily dosage containing from 10 9 to 10 11 platelets per square meter of patient surface area.
13. The method of claim 12 , wherein the daily dosage contains about 10 11 platelets per square meter of patient surface area.
14. The method of claim 12 , wherein the daily dosage is administered in a single administration.
15. The method of claim 12 , wherein the daily dosage is administered at a frequency of from one to seven times in a one-week period.